A Two-Part, Open-Label Systemic Gene Delivery Study to Evaluate the Safety and Expression of RO7494222 (SRP-9001) in Subjects Under the Age of Four With Duchenne Muscular Dystrophy
Latest Information Update: 16 Jun 2025
At a glance
- Drugs Delandistrogene moxeparvovec (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Acronyms ENVOL
Most Recent Events
- 15 Jun 2025 According to a Roche media release, The study is on temporary clinical hold in Europe and the UK.
- 04 Apr 2025 According to a Sarepta Therapeutics media release, Following the safety update on acute liver failure European Union (EU) reference member country authorities requested that the independent data monitoring committee (DMC) meet to review the adverse event. While the analysis is being finalized, recruitment and dosing in certain clinical studies of ELEVIDYS are temporarily halted. This study has been affected by the temporary halt.
- 17 Feb 2025 Planned primary completion date changed from 30 Nov 2032 to 30 May 2033.